Analytical Method Maintenance - Several steps can be taken to maintain test method suitability after the formal completion of the analytical method validation studies - BioPharm International

ADVERTISEMENT

Analytical Method Maintenance
Several steps can be taken to maintain test method suitability after the formal completion of the analytical method validation studies


BioPharm International


Understanding the Relationship of All Components

There are numerous ways that process and method performance knowledge can be used to monitor and improve overall process and product quality. In reality, unlimited time and resources are not always available and we should first identify the most critical components and maintain committed to implement critical improvements before we get lost in too much data. A hypothetical example is provided to illustrate how acceptance criteria for AMTs and AMMs could be derived with respect to estimated probabilities for 1A–B and 2A–B. Following from this example, potential improvements are discussed to illustrate what could be done to reduce the undesirable probabilities for cases 1B and 2A-B.

A potency bioassay is used for downstream in-process and final container testing of a licensed biopharmaceutical drug. This method is monitored in our AMM program. After months of commercial production, transfer of this analytical method to a different laboratory for product release testing is needed. If the downstream in-process stage is yielding inconsistent potency results (Table 2), the following data should be reviewed:

  • process development
  • process validation
  • AMD
  • AMV
  • historical process
  • method performance (assay control) data.


Table 2. Historical process, sampling, assay performance data, and suggested limits for accuracy and (intermediate) precision
We may want to start with the easiest variance component, the assay variance, as monitored with the assay control. Figure 1 illustrates the relationship between the assay performance and observed recent SPC potency results (last n = 60).

The statistical likelihood for failures now needs to be estimated and a component variance analysis performed to estimate the contribution of each component. Focus can then be put on how to set limits on post-validation activities from understanding the potential impact on the likelihood for all cases (1A–2B) to occur. The situation can be most effectively improved by primarily having in mind patient safety, dosing, and regulatory expectations, but secondarily also the firm as the need to pass specifications and stay profitable is important. Similar to propagation-of-error calculations, an estimate for the sampling variance (batch-uniformity, stability, protein adsorption losses, etc.), could allow immediate estimation of the actual (true) process performance for potency by simply solving for it from Equation 1 (V = variance):

Equation 1: [V observed for process ] 2 = [V assay ] 2 + [V sampling/batch uniformity ]2 + [V actual for proces s] 2

Equation 2: [CV% Potency] 2 = 1/n [ (CV% Inter-assay) 2 + (CV% Sampling) 2 /(# sampling units) + (CV% Intra-assay) 2 /( # sampling units) x (replicates for each sample)]


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here